Close Menu

NEW YORK — Predictive Oncology said on Friday that it has signed a letter of intent to acquire biomedical analytics and computational biology firm Quantitative Medicine (QM).

Terms of the acquisition, which is expected to close in the first half of the year, were not disclosed.

According to Predictive Oncology, QM has developed a computational drug discovery platform, called Core, that can predict the main effects of drugs on disease-associated targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.